<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172925</url>
  </required_header>
  <id_info>
    <org_study_id>2009-TIDAL</org_study_id>
    <nct_id>NCT01172925</nct_id>
  </id_info>
  <brief_title>Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer</brief_title>
  <acronym>TIDAL</acronym>
  <official_title>Randomized Phase II Crossover Study of Tiotropium For Dyspnea in Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for&#xD;
      patients and upsetting for their family. Although drugs like morphine and oxygen can help&#xD;
      some patients feel better, they don't help everybody, and they are not used in patients with&#xD;
      early symptoms. More relief is needed for these patients. The investigators are studying a&#xD;
      drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways&#xD;
      to allow easier breathing. Every patient will get the drug but also a placebo, in a random&#xD;
      (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they&#xD;
      feel better with the drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 question Cancer Dyspnea Scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>10 point Dyspnea numeric scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 point Cough scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume 1 second (L/s) and Forced Vital Capacity (L)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>NSCLC</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Inhaler</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven incurable stage IIIb or stage IV non-small cell&#xD;
             lung cancer.&#xD;
&#xD;
          2. Dyspnea as defined by a score of 2 or higher on the 10-point Dyspnea Numeric Scale&#xD;
             (Appendix 2).&#xD;
&#xD;
          3. New dyspnea or worsening dyspnea within the last 6 months per patient reporting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18.&#xD;
&#xD;
          2. An FEV1 / FVC ratio &lt; 0.7 with an FEV1 of &lt; 80% predicted post-bronchodilator.&#xD;
&#xD;
          3. Life expectancy &lt; 3 months.&#xD;
&#xD;
          4. Significant worsening of dyspnea over the last week such that an acute cardiac or&#xD;
             respiratory condition is considered likely (e.g. pneumonia, heart failure).&#xD;
&#xD;
          5. Myocardial infarction within the previous month.&#xD;
&#xD;
          6. Heart rate ≥ 120.&#xD;
&#xD;
          7. Active tuberculosis or tuberculosis receiving antibiotic therapy.&#xD;
&#xD;
          8. Current or previous use of ipratropium, tiotropium, or oxitropium (see Appendix 6).&#xD;
&#xD;
          9. Sensitivity to atropine.&#xD;
&#xD;
         10. Pre-existing diagnosis of asthma or moderate to severe Chronic Obstructive Pulmonary&#xD;
             Disease&#xD;
&#xD;
         11. Use of beta-adrenergic bronchodilators more than once per week.&#xD;
&#xD;
         12. Use of experimental therapy with known cholinergic or adrenergic effects.&#xD;
&#xD;
         13. Uncontrolled glaucoma.&#xD;
&#xD;
         14. Urinary retention.&#xD;
&#xD;
         15. An active upper or lower respiratory infection or having taken antibiotics for any&#xD;
             recent respiratory infection within 4 weeks.&#xD;
&#xD;
         16. Symptomatic pleural or pericardial effusion.&#xD;
&#xD;
         17. Evidence of reversible proximal endobronchial obstruction.&#xD;
&#xD;
         18. Oxygen saturation &lt; 90%.&#xD;
&#xD;
         19. A hemoglobin of &lt; 100 g/litre. Testing is to be within 4 weeks of randomization.&#xD;
&#xD;
         20. Calculated or urine creatinine clearance ≤ 50 mL/min (see Appendix 5 for calculation).&#xD;
             Testing it to be within 4 weeks of randomization.&#xD;
&#xD;
         21. Weight loss &gt; 10% of usual body weight within 6 months.&#xD;
&#xD;
         22. Known pregnancy or lactating.&#xD;
&#xD;
         23. Unable to independently fill out quality of life forms or give informed consent.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Goffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre and McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Goffin, MD</last_name>
    <phone>905-387-9495</phone>
    <phone_ext>64603</phone_ext>
    <email>goffinj@hhsc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry McFarlan, RN</last_name>
    <phone>905-387-9495</phone>
    <phone_ext>64407</phone_ext>
    <email>smcfarla@hhsc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry McFarlan, RN</last_name>
      <phone>905-387-9495</phone>
      <phone_ext>64407</phone_ext>
      <email>smcfarla@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>John Goffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>John Goffin</investigator_full_name>
    <investigator_title>Associate Prof</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>dyspnea</keyword>
  <keyword>phase II</keyword>
  <keyword>crossover</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

